Acalabrutinib Maleate Monohydrate is a second-generation, highly selective Bruton's tyrosine kinase (BTK) inhibitor indicated for the treatment of certain B-cell malignancies, including chronic lymphocytic… Read more
Acalabrutinib Maleate Monohydrate is a second-generation, highly selective Bruton's tyrosine kinase (BTK) inhibitor indicated for the treatment of certain B-cell malignancies, including chronic lymphocytic leukemia and mantle cell lymphoma. By inhibiting BTK activity, this pharmaceutical agent blocks specific signaling pathways responsible for the proliferation of malignant B-cells. This category provides comprehensive analytical tools necessary for pharmaceutical research and quality control, including Acalabrutinib Maleate Monohydrate reference standards. These materials are critical for impurity profiling, method development, and validation to ensure regulatory compliance. The collection also includes related pharmacopeial and non-pharmacopeial impurities, metabolites, and stable isotope-labelled compounds, which serve as essential internal standards for mass spectrometry-based assays. Pharmaceutical laboratories rely on these high-quality compounds to accurately identify and quantify potential impurities and degradation products throughout the lifecycle of drug development and manufacturing.